Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

UK: EWHC (Pat): “Obvious to try” is obviously not obvious: Omnipharm v Merial (IPKat) (EPLAW)

US: Federal Circuit limits courts’ ability to consider validity of claims not actually asserted against defendant: Streck v Research & Diagnostic Systems (PatLit) (Patently-O)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

WHO reform efforts to consider new modalities for engagement with NGOs, foundations, partnerships and for-profit-organizations (KEI) (IP Watch)

Johnson & Johnson denies Patent Pool licences for HIV medicines for the poor (IP Watch)

Free resources for biomed and biotech research (Patent Quality Matters)

EU: Is the ECJ’s judgment in Medeva in line with EPC (2000)? (Kluwer Patent Blog)

EU: EPO TBoA: EPC 2000 and hidden traps for loss of rights: Hadasit Medical Research Services v EyeGate Pharma (EPLAW)

EU: After the recent batch of SPC rulings, where are we? (The SPC Blog) (The SPC Blog)

France: Reform on appearance of generic drugs and IP rights is finally adopted (Class 46)

India: Practice pointer series: Brief on patenting diagnostic methods in India (IIPRD)

Latin America: Enforcement of TRIPs in Latin America and its contributions to research and health (IP tango)

Netherlands: District Court of The Hague rules that insurance company auction for preferred drug suppliers during patent (SPC) term does not constitute patent infringement: Pfizer v UVIT and VGZ (EPLAW)

US: Yet another study suggesting changes in Hatch-Waxman regime (Patent Docs)

US: KEI files amicus brief in BRCA gene patent case: AMP v Myriad (KEI)

US: Federal Circuit upholds preliminary injunction over dissent: Celsis v CellzDirect (Patently-O) (Patent Docs)

US: Federal Circuit limits courts’ ability to consider validity of claims not actually asserted against defendant: Streck v Research & Diagnostic Systems (PatLit) (Patently-O)

US: CAFC: Abbott loses patent rights due to gap in consultant contract: Abbott Point of Care v Epocal (Patently-O)

 

Products

ACTOplus Met XR (Pioglitazone and Metformin)  – US: Takeda files patent infringement complaint against Mylan in response to Para IV challenge (Patent Docs)

Atorvastatin – Spain: Supreme Court dismisses revocation action against patent protecting calcium salt of atorvastatin (Kluwers Patent Blog)

Diglycidyl compounds – Germany: Federal Supreme Court guidance on doctrine of equivalents where multiple solutions contained in description but only single solution claimed (EPLAW)

Diovan (Valsartan) – Loss of jobs at Novartis preceding expiry of Diovan patent protection (IPBiz)

Fibronil – UK: EWHC (Pat): “Obvious to try” is obviously not obvious: Omnipharm v Merial (IPKat) (EPLAW)

Intuniv (Guanfacine) – US: Shire files patent infringement complaint against Sandoz in response to ANDA amendment (to include additional dosages) (Patent Docs)

Plavix (Clopidogrel) – Canada: Double recovery in transnational patent litigation: Apotex v Sanofi (IPKat)